Medical Technology Company Launches Fair Deal Agreement: Reports Major Revenue Increase
This patent enhances the company's intellectual property portfolio and reinforces its position as a leader in the dermatological treatment landscape.
As an investor it's important to stay updated with major news. Get real-time stock market alerts, news, and research by creating an account here.
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company known for its non-invasive, minimally invasive, and cost-effective treatments for oncological and non-oncological conditions, has unveiled its financial outcomes for the first quarter ended March 31, 2024. The results present a substantial revenue increase and underscore the successful launch of a novel recurring revenue program aimed at enhancing equipment accessibility and usage flexibility for healthcare providers.
Stellar Financial Performance
For the quarter ending March 31, 2024, Sensus Healthcare reported revenues of $10.7 million, a striking increase from the $3.4 million recorded in the same period the previous year. This remarkable growth of 214% is attributed to heightened sales of superficial radiotherapy (SRT and IG-SRT) units, highlighting the expanding acceptance and application of Sensus’s technology in the medical field. The company shipped 26 SRT systems during the quarter, more than doubling the total from the previous year's 10 systems. Such a surge in shipments indicates a growing demand for Sensus’s innovative treatment solutions across various healthcare settings. A further testament to Sensus Healthcare’s upward trajectory is the report of a net income of $2.3 million, or $0.14 per diluted share, a significant turnaround from a net loss of $1.9 million, or $0.12 per share, in the first quarter of 2023. This profitability reflects the company’s efficient management and strategic initiatives, which have evidently borne fruit. Strengthening its financial position, Sensus ended the quarter with $14.7 million in cash and cash equivalents, maintaining a debt-free status. Accounts receivable stood at $19.6 million as of March 31, 2024, up from $10.6 million at the end of December 2023, indicating robust sales activity and effective receivables management.
Among the key highlights of the quarter was the launch of the "Fair Deal Agreement" recurring revenue program for the SRT-100 Vision™ (IG-SRT). This innovative program offers an equipment placement option to complement the existing fair market value lease program, addressing the capital allocation needs of healthcare providers while presenting an attractive economic model. The program's simplicity—whereby increased patient treatments translate directly into higher practice revenue—has garnered significant interest, promising a new revenue stream for participating practices. Sensus Healthcare also actively participated in notable trade conferences, including the Winter Clinical and South Beach Symposium, and the American Academy of Dermatology Annual Meeting. These events provided an excellent platform to showcase the Fair Deal Agreement program and other products, drawing significant attention and engagement from attendees. Further solidifying its commitment to enhancing patient safety and expanding treatment indications, Sensus engaged CureRays to provide oversight and supervision for customers involved in the recurring revenue program. CureRays will also spearhead clinical studies to explore new applications for SRT, starting with inflammatory diseases. Sensus announced the issuance of a U.S. patent for treatment planning capabilities of the SRT-100 Vision System (IG-SRT). This patent enhances the company's intellectual property portfolio and reinforces its position as a leader in the dermatological treatment landscape.
Expanding Global Reach
Marking its first foray into Asia, Sensus sold an SRT-100 Vision System (IG-SRT) to Far Eastern Memorial Hospital in Taiwan. This milestone signifies the company's expanding global footprint and the universal appeal of its treatment solutions. Additionally, Sensus made its first commercial sale of an SRT-100 for veterinary use outside the U.S., to Chavat Da’at, the Veterinary Specialist Referral Center Knowledge Farm at Beit Verl College in Tel Aviv. This diversification into veterinary medicine opens up a new avenue for growth, providing a gentler radiotherapy option to treat tumors in pets. Joe Sardano, Chairman, and Chief Executive Officer of Sensus Healthcare, expressed satisfaction with the quarter's results, attributing the success to the company's continued momentum and the strategic introduction of the Fair Deal Agreement program. He emphasized the importance of SRT as a non-invasive, efficacious modality for treating non-melanoma skin cancer and the positive reception of the company's sales options.
Sensus Healthcare specializes in developing, manufacturing, and selling highly effective, non-invasive, minimally invasive, and cost-effective treatments for both oncological and non-oncological conditions. The company is known for its innovative approach to skin cancer treatment, particularly with its Superficial Radiation Therapy (SRT) systems, which offer a non-surgical option for patients. This technology targets skin cancer cells with precise, shallow radiation doses, providing an alternative to traditional surgery without the need for cutting, bleeding, or stitching.
The recent news about the significant increase in revenues and the launch of the "Fair Deal Agreement" recurring revenue program could have a positive impact on Sensus Healthcare and its stock in the following ways:
Revenue Growth: The reported increase in revenues from $3.4 million to $10.7 million represents significant growth, which could boost investor confidence in the company's growth trajectory and operational efficiency. Such a robust financial performance might attract more investors, potentially driving up the stock price.
Improved Profitability: The transition from a negative Adjusted EBITDA of $2.7 million in the prior-year quarter to a positive $3.0 million signals a substantial improvement in profitability. This turnaround can be viewed favorably by the market, suggesting that the company is managing its expenses well and capitalizing on its revenue streams effectively.
Innovative Revenue Program: The introduction of the "Fair Deal Agreement" could be a game-changer. By offering an equipment placement option that complements the fair market value lease program, Sensus Healthcare is making its SRT systems more accessible to a broader range of healthcare providers. This initiative could lead to an expansion in the company’s customer base, increased utilization of its systems, and ultimately, higher recurring revenues.
Market Sentiment: Positive financial results, coupled with strategic initiatives aimed at long-term growth, can improve market sentiment towards the company’s stock. Investors are likely to see Sensus Healthcare as a thriving enterprise with a solid plan for sustainability and expansion, making its stock more attractive.
American Healthcare Growth Stocks to Watch:
Teladoc Health, Inc. (TDOC) - A leader in telemedicine and virtual healthcare services experiencing rapid growth.
Moderna, Inc. (MRNA) - Known for its mRNA technology used in COVID-19 vaccines, Moderna is expanding its pipeline into other infectious diseases and cancer treatments.
Guardant Health, Inc. (GH) - Specializes in advanced cancer diagnostics using blood tests, with a strong focus on precision oncology.
Intuitive Surgical, Inc. (ISRG) - A pioneer in robotic-assisted surgery, continuously innovating in minimally invasive surgical technologies.
Exact Sciences Corp. (EXAS) - Offers molecular screening tests for colorectal cancer and is expanding into other cancer detection tests.
Upcoming News Investors Should Look Out For:
Expansion Updates: Any announcements regarding new partnerships, market expansions, or further adoption of the "Fair Deal Agreement" program.
Product Development: News about advancements in SRT technology, new product launches, or updates to existing systems could signal growth potential.
Financial Forecasts: Updated revenue or profit forecasts from the company, reflecting the impact of the "Fair Deal Agreement" and other strategic initiatives.
Regulatory Approvals: Information on regulatory approvals for new treatments or indications for existing products, which could open up new market opportunities.
Industry Events: Participation in upcoming healthcare conferences or symposiums where Sensus Healthcare might present data, showcase products, or announce collaborations.
Investors interested in Sensus Healthcare should closely monitor these areas for any developments, as they could significantly influence the company's valuation and stock performance in the near term.
Disclaimer: This article contains forward-looking statements based on current expectations and projections about future events. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Sensus Healthcare undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. This press release includes supplemental financial information that has been derived through methodologies not aligned with Generally Accepted Accounting Principles in the United States (GAAP). In its evaluation of the company's operational performance, Sensus Healthcare's management utilizes Adjusted EBITDA, a financial measure that is not recognized by GAAP. It is important to acknowledge that Adjusted EBITDA should not be seen as a replacement for measures based on GAAP, nor should it be considered an alternative for operating results as determined within the GAAP framework. The belief of Sensus Healthcare's management is that the presentation of Adjusted EBITDA, which excludes the effects of interest, income taxes, depreciation, amortization, and stock-compensation expense, provides valuable supplementary information. This additional insight is deemed crucial for a thorough understanding of Sensus Healthcare’s financial achievements. However, it is imperative to note that non-GAAP financial measures lack a standardized definition under GAAP, leading to potential discrepancies in the methods of calculation used by different entities compared to those employed by Sensus Healthcare. Adjusted EBITDA is provided as an additional resource alongside GAAP financial metrics, supporting investors who engage with analyses that adjust GAAP financial figures to omit elements that may conceal the true operational performance or affect the comparability of financial results.